Altered immune profile from pre-diabetes to manifestation of type 1 diabetes

Diabetes Research and Clinical Practice

Volumn 100, Issue 1, 2013, Pages 74-84

  Rydén, Anna ^a   Faresjö, Maria ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b JÖNKÖPING UNIVERSITY   (Sweden)

Author keywords

Chemokines; Cytokines; Pre diabetes; Th1; Th2; Type 1 diabetes

Indexed keywords

AUTOANTIGEN; CHAPERONIN 60; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUTAMATE DECARBOXYLASE 65; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE; PLACEBO; RANTES; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DISEASE DURATION; FEMALE; FIRST DEGREE RELATIVE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATORY CELL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; ONSET AGE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

ADOLESCENT; AGE OF ONSET; CHAPERONIN 60; CHEMOKINES; CHILD; CHILD, PRESCHOOL; CYTOKINES; DIABETES MELLITUS, TYPE 1; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GLUTAMATE DECARBOXYLASE; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MITOCHONDRIAL PROTEINS; PREDIABETIC STATE; REAL-TIME POLYMERASE CHAIN REACTION; SWEDEN; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84876711566     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.01.014     Document Type: Article

References (50)

1. Gale E.A. The discovery of type 1 diabetes. Diabetes 2001, 50(2):217-226.
2. In't Veld P. Insulitis in human type 1 diabetes: the quest for an elusive lesion. Islets 2011, 3(4).
3. Eisenbarth G.S. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986, 314(21):1360-1368.
4. Liblau R.S., Wong F.S., Mars L.T., Santamaria P. Autoreactive CD8T cells in organ-specific autoimmunity: emerging targets for therapeutic intervention. Immunity 2002, 17(1):1-6.
5. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173.
6. Mosmann T.R., Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996, 17(3):138-146.
7. Taylor A., Verhagen J., Blaser K., Akdis M., Akdis C.A. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 2006, 117(4):433-442.
8. Atkinson M.A., Wilson S.B. Fatal attraction: chemokines and type 1 diabetes. J Clin Invest 2002, 110(11):1611-1613.
9. Schrum S., Probst P., Fleischer B., Zipfel P.F. Synthesis of the CC-chemokines MIP-1alpha: MIP-1beta, and RANTES is associated with a type 1 immune response. J Immunol 1996, 157(8):3598-3604.
10. O'Garra A., McEvoy L.M., Zlotnik A. T-cell subsets: chemokine receptors guide the way. Curr Biol 1998, 8(18):R646-R649.
11. Bradley L.M., Asensio V.C., Schioetz L.K., Harbertson J., Krahl T., Patstone G., et al. Islet-specific Th1: but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J Immunol 1999, 162(5):2511-2520.
12. Wing K., Suri-Payer E., Rudin A. CD4+ CD25+-regulatory T cells from mouse to man. Scand J Immunol 2005, 62(1):1-15.
13. Maggi E., Cosmi L., Liotta F., Romagnani P., Romagnani S., Annunziato F. Thymic regulatory T cells. Autoimmun Rev 2005, 4(8):579-586.
14. Leslie R.D., Atkinson M.A., Notkins A.L. Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes. Diabetologia 1999, 42(1):3-14.
15. Elias D., Prigozin H., Polak N., Rapoport M., Lohse A.W., Cohen I.R. Autoimmune diabetes induced by the beta-cell toxin STZ. Immunity to the 60-kDa heat shock protein and to insulin. Diabetes 1994, 43(8):992-998.
16. Gale E.A., Bingley P.J., Emmett C.L., Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004, 363(9413):925-931.
17. Karlsson M.G., Lawesson S.S., Ludvigsson J. Th1-like dominance in high-risk first-degree relatives of type I diabetic patients. Diabetologia 2000, 43(6):742-749.
18. Faresjo M.K., Ernerudh J., Berlin G., Garcia J., Ludvigsson J. The immunological effect of photopheresis in children with newly diagnosed type 1 diabetes. Pediatr Res 2005, 58(3):459-466.
19. Kivling A., Nilsson L., Faresjo M. How and when to pick up the best signals from markers associated with T-regulatory cells?. J Immunol Methods 2009, 345(1-2):29-39.
20. Jonson C.O., Pihl M., Nyholm C., Cilio C.M., Ludvigsson J., Faresjo M. Regulatory T cell-associated activity in photopheresis-induced immune tolerance in recent onset type 1 diabetes children. Clin Exp Immunol 2008, 153(2):174-181.
21. Karlsson Faresjo M.G., Ludvigsson J. Diminished Th1-like response to autoantigens in children with a high risk of developing type 1 diabetes. Scand J Immunol 2005, 61(2):173-179.
22. Hedman M., Ludvigsson J., Faresjo M.K. Nicotinamide reduces high secretion of IFN-gamma in high-risk relatives even though it does not prevent type 1 diabetes. J Interferon Cytokine Res 2006, 26(4):207-213.
23. Gupta S. Immunotherapies in diabetes mellitus type 1. Med Clin North Am 2012, 96(3):621-34. xi.
24. Chen W., Salojin K.V., Mi Q.S., Grattan M., Meagher T.C., Zucker P., et al. Insulin-like growth factor (IGF)-I/IGF-binding protein-3 complex: therapeutic efficacy and mechanism of protection against type 1 diabetes. Endocrinology 2004, 145(2):627-638.
25. Katz J.D., Wang B., Haskins K., Benoist C., Mathis D. Following a diabetogenic T cell from genesis through pathogenesis. Cell 1993, 74(6):1089-1100.
26. Mathis D., Vence L., Benoist C. Beta-Cell death during progression to diabetes. Nature 2001, 414(6865):792-798.
27. Yang X.D., Tisch R., Singer S.M., Cao Z.A., Liblau R.S., Schreiber R.D., et al. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 1994, 180(3):995-1004.
28. Meyers A.J., Shah R.R., Gottlieb P.A., Zipris D. Altered toll-like receptor signaling pathways in human type 1 diabetes. J Mol Med 2010, 88(12):1221-1231.
29. Dogan Y., Akarsu S., Ustundag B., Yilmaz E., Gurgoze M.K. Serum IL-1beta, IL-2, and IL-6 in insulin-dependent diabetic children. Mediators Inflamm 2006, 2006(1):59206.
30. Pohlers D., Siegling A., Buchner E., Schmidt-Weber C.B., Palombo-Kinne E., Emmrich F., et al. Expression of cytokine mRNA and protein in joints and lymphoid organs during the course of rat antigen-induced arthritis. Arthritis Res Ther 2005, 7(3):R445-R457.
31. Simon J., Surber R., Kleinstauber G., Petrow P.K., Henzgen S., Kinne R.W., et al. Systemic macrophage activation in locally-induced experimental arthritis. J Autoimmun 2001, 17(2):127-136.
32. van der Poll T., Keogh C.V., Guirao X., Buurman W.A., Kopf M., Lowry S.F. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis 1997, 176(2):439-444.
33. Kristiansen O.P., Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent?. Diabetes 2005, 54(Suppl 2):S114-S124.
34. Ryden A., Stechova K., Durilova M., Faresjo M. Switch from a dominant Th1-associated immune profile during the pre-diabetic phase in favour of a temporary increase of a Th3-associated and inflammatory immune profile at the onset of type 1 diabetes. Diabetes Metab Res Rev 2009, 25(4):335-343.
35. Faresjo M.K., Vaarala O., Thuswaldner S., Ilonen J., Hinkkanen A., Ludvigsson J. Diminished IFN-gamma response to diabetes-associated autoantigens in children at diagnosis and during follow up of type 1 diabetes. Diabetes Metab Res Rev 2006, 22(6):462-470.
36. Karlsson Faresjo M.G., Ernerudh J., Ludvigsson J. Cytokine profile in children during the first 3 months after the diagnosis of type 1 diabetes. Scand J Immunol 2004, 59(5):517-526.
37. Hanifi-Moghaddam P., Kappler S., Seissler J., Muller-Scholze S., Martin S., Roep B.O., et al. Altered chemokine levels in individuals at risk of Type 1 diabetes mellitus. Diabet Med 2006, 23(2):156-163.
38. Cameron M.J., Arreaza G.A., Grattan M., Meagher C., Sharif S., Burdick M.D., et al. Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes. J Immunol 2000, 165(2):1102-1110.
39. Zhernakova A., Alizadeh B.Z., Eerligh P., Hanifi-Moghaddam P., Schloot N.C., Diosdado B., et al. Genetic variants of RANTES are associated with serum RANTES level and protection for type 1 diabetes. Genes Immun 2006, 7(7):544-549.
40. Schall T.J., Jongstra J., Dyer B.J., Jorgensen J., Clayberger C., Davis M.M., et al. A human T cell-specific molecule is a member of a new gene family. J Immunol 1988, 141(3):1018-1025.
41. Song A., Nikolcheva T., Krensky A.M. Transcriptional regulation of RANTES expression in T lymphocytes. Immunol Rev 2000, 177:236-245.
42. de Waal Malefyt R., Figdor C.G., Huijbens R., Mohan-Peterson S., Bennett B., Culpepper J., et al. Effects of IL-13 on phenotype: cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol 1993, 151(11):6370-6381.
43. Deepak P., Kumar S., Kishore D., Acharya A. IL-13 from Th2-type cells suppresses induction of antigen-specific Th1 immunity in a T-cell lymphoma. Int Immunol 2010, 22(1):53-63.
44. Skyler J.S., Krischer J.P., Wolfsdorf J., Cowie C., Palmer J.P., Greenbaum C., et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005, 28(5):1068-1076.
45. Nanto-Salonen K., Kupila A., Simell S., Siljander H., Salonsaari T., Hekkala A., et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008, 372(9651):1746-1755.
46. Raz I., Elias D., Avron A., Tamir M., Metzger M., Cohen I.R. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001, 358(9295):1749-1753.
47. Huurman V.A., van der Meide P.E., Duinkerken G., Willemen S., Cohen I.R., Elias D., et al. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin Exp Immunol 2008, 152(3):488-497.
48. Eldor R., Kassem S., Raz I. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results. Diabetes Metab Res Rev 2009, 25(4):316-320.
49. Agardh C.D., Cilio C.M., Lethagen A., Lynch K., Leslie R.D., Palmer M., et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005, 19(4):238-246.
50. Ludvigsson J., Faresjo M., Hjorth M., Axelsson S., Cheramy M., Pihl M., et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008, 359(18):1909-1920.